Stock JNJB34 JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Johnson & Johnson Sao Paulo

Equities

JNJB34

BRJNJBBDR002

Market Closed - Sao Paulo
Other stock markets
 16:05:00 2024-06-28 EDT 		5-day change 1st Jan Change
54.45 BRL +2.08% Intraday chart for Johnson & Johnson +0.70% +8.04%
06-28 Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial MT
06-28 J&J Unit's Rybrevant Combo Gets EU Approval MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients
PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)
AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program
AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.
AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications
AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
BU
J&J commits five-year investment in Italian medicine manufacturing
AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study
AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up
PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJB34 Stock
  5. News Johnson & Johnson
  6. Press Releases